Rate Video

ASH 2015 | Overview of RESONATE-2 clinical trial of ibrutinib in CLL

John Gribben and Stephan Stilgenbauer • 4 Dec 2015

Chronic Lymphocytic Leukemia Ibrutinib

At the American Society of Hematology (ASH) 2015 Annual Meeting, John Gribben, MD, DSc and Stephan Stilgenbauer, MD discuss the use of ibrutinib as front-line therapy in chronic lymphocytic leukemia (CLL).

The President's debrief: what to look out for at EHA 2020

CAR-T vs bispecific antibodies for lymphoma

David Maloney et al.

Highlights from Day 2: addressing challenges in CAR-T therapy for ALL, AML, CLL & more…

David Maloney et al. • 30 Apr 2022

The current status of CLL treatment and how clinical practice will change

John Gribben • 16 Sep 2016

Summary of CLL trials presented at ASH 2016

Stephan Stilgenbauer • 2 Dec 2016

Highlights of ASH in CLL

John Gribben et al. • 4 Dec 2015

Developments that are changing the treatment of CLL - current and future drugs

Stephan Stilgenbauer • 16 Sep 2016

Current and future advancements in the treatment of CLL

Stephan Stilgenbauer

Related Videos

Updated PFS results of the GAIA/CLL13 trial

Barbara Eichhorst • 20 Jun 2022

The benefits of next-generation BTK inhibitors in CLL

Barbara Eichhorst • 20 Jun 2022

BTK inhibitor-associated adverse events in patients with CLL

Barbara Eichhorst • 20 Jun 2022

Selection for time-limited & continuous therapy in CLL

Barbara Eichhorst • 20 Jun 2022